Serotonin Linked to Faster Heart Valve Disease in Certain SSRI Users

Scientists have identified a link between serotonin activity and the accelerated progression of degenerative mitral regurgitation, a common heart‑valve disorder. The findings, reported in a recent peer‑reviewed study, indicate that patients who use selective serotonin‑reuptake inhibitor (SSRI) antidepressants and possess a particular genetic variant associated with serotonin signaling develop more severe valve damage at a younger age than non‑users. The research team analyzed clinical records and genetic data from individuals diagnosed with the condition, observing a statistically significant trend toward earlier onset of severe mitral valve dysfunction among the SSRI‑exposed cohort.

The study suggests that heightened serotonin activity may exacerbate the structural deterioration of the mitral valve, potentially prompting surgical intervention sooner than typically expected. While the results do not establish causation, they highlight the need for clinicians to consider medication history and genetic factors when monitoring patients with degenerative mitral regurgitation. Further investigations are planned to confirm the mechanism and to assess whether alternative antidepressant strategies could mitigate the observed risk.